STAAR Surgical Company (STAA)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.32B
Last updated: Nov 17, 2026 at 11:05 AM ET
STAAR Surgical Company (STAA) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, STAAR Surgical Company reported EPS of $0.26, above the $0.05 estimate. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
STAA's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
STAA Earnings Call
The latest STAA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, STAA beat 31, missed 3 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $83.41M, down 11.9% from $94.73M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.26 | $0.05 | N/A | +420.00% | Beat | -13.3% | 7 | 0 up, 1 down | Nov 4, 2026 | $83.41M |
| Jun 30, 2026 | $0.18 | $0.05 | N/A | +260.00% | Beat | N/A | 8 | 4 up, 0 down | Aug 12, 2026 | $93.53M |
| Mar 31, 2026 | $0.29 | $0.08 | -$0.13 - $0.16 | +262.50% | Beat | N/A | 6 | 3 up, 1 down | May 13, 2026 | $93.52M |
| Dec 31, 2025 | $0.01 | $0.15 | $0.06 - $0.28 | -94.78% | Miss | N/A | 6 | 1 up, 1 down | Mar 3, 2026 | $57.80M |
| Sep 30, 2025 | $0.30 | $0.05 | N/A | +500.00% | Beat | +50.0% | 5 | 1 up, 1 down | Nov 5, 2025 | $94.73M |
| Jun 30, 2025 | -$0.13 | -$0.56 | -$0.70 - -$0.39 | +76.79% | Beat | -133.3% | 7 | 1 up, 1 down | Aug 6, 2025 | $44.32M |
| Mar 31, 2025 | -$1.00 | -$0.60 | -$0.78 - -$0.49 | -66.67% | Miss | -1009.1% | 10 | 0 up, 6 down | May 7, 2025 | $42.59M |
| Dec 31, 2024 | -$0.69 | -$0.03 | -$0.13 - $0.10 | N/A | N/A | -531.3% | 8 | 2 up, 0 down | Feb 11, 2025 | $48.95M |
| Sep 30, 2024 | $0.20 | $0.18 | $0.09 - $0.21 | +11.11% | Beat | -33.3% | 8 | 0 up, 0 down | Oct 30, 2024 | $88.59M |
| Jun 30, 2024 | $0.39 | $0.25 | $0.19 - $0.29 | +56.00% | Beat | -2.5% | 9 | 0 up, 0 down | Aug 7, 2024 | $99.00M |
| Mar 31, 2024 | $0.11 | $0.06 | -$0.05 - $0.11 | +83.33% | Beat | -38.9% | 9 | 3 up, 0 down | May 7, 2024 | $77.36M |
| Dec 31, 2023 | $0.16 | $0.17 | $0.06 - $0.30 | -5.88% | Miss | +14.3% | 10 | 0 up, 0 down | Feb 26, 2024 | $76.27M |
| Sep 30, 2023 | $0.30 | $0.18 | $0.11 - $0.26 | +66.67% | Beat | -18.9% | 10 | 0 up, 0 down | Nov 1, 2023 | $80.31M |
| Jun 30, 2023 | $0.40 | $0.30 | N/A | +33.33% | Beat | -4.8% | 11 | 2 up, 0 down | Aug 2, 2023 | $92.31M |
| Mar 31, 2023 | $0.18 | $0.09 | -$0.03 - $0.18 | +100.00% | Beat | -37.9% | 11 | 0 up, 0 down | May 3, 2023 | $73.53M |
| Dec 31, 2022 | $0.14 | $0.14 | $0.01 - $0.16 | 0.00% | In line | -26.3% | 10 | 0 up, 0 down | Feb 21, 2023 | $64.04M |
| Sep 30, 2022 | $0.37 | $0.21 | N/A | +76.19% | Beat | +76.2% | 9 | 0 up, 0 down | Nov 2, 2022 | $76.05M |
| Jun 30, 2022 | $0.42 | $0.23 | N/A | +82.61% | Beat | +55.6% | N/A | 0 up, 0 down | Aug 10, 2022 | $81.10M |
| Mar 31, 2022 | $0.29 | $0.15 | N/A | +93.33% | Beat | +45.0% | 8 | 0 up, 0 down | May 4, 2022 | $63.20M |
| Dec 31, 2021 | $0.19 | $0.19 | N/A | 0.00% | In line | +35.7% | 7 | 0 up, 0 down | Feb 23, 2022 | $59.00M |
| Sep 30, 2021 | $0.21 | $0.17 | N/A | +23.53% | Beat | +40.0% | 5 | N/A | Nov 3, 2021 | $58.35M |
| Jun 30, 2021 | $0.27 | $0.09 | N/A | +200.00% | Beat | +800.0% | 7 | N/A | Aug 4, 2021 | $62.37M |
| Mar 31, 2021 | $0.20 | $0.03 | -$0.06 - $0.03 | +566.67% | Beat | +400.0% | 6 | N/A | May 5, 2021 | $50.75M |
| Dec 31, 2020 | $0.14 | $0.14 | N/A | 0.00% | In line | +16.7% | 6 | N/A | Feb 24, 2021 | $46.00M |
| Sep 30, 2020 | $0.15 | $0.09 | N/A | +66.67% | Beat | +25.0% | 6 | N/A | Nov 4, 2020 | $47.08M |
| Jun 30, 2020 | $0.03 | $0.03 | N/A | 0.00% | In line | -78.6% | 6 | N/A | Aug 5, 2020 | $35.19M |
| Mar 31, 2020 | $0.04 | $0.03 | N/A | +33.33% | Beat | -55.6% | 5 | N/A | May 6, 2020 | $35.19M |
| Dec 31, 2019 | $0.12 | $0.12 | N/A | 0.00% | In line | +71.4% | 5 | N/A | Feb 26, 2020 | $38.88M |
| Sep 30, 2019 | $0.12 | $0.08 | N/A | +50.00% | Beat | +71.4% | 4 | N/A | Oct 30, 2019 | $39.05M |
| Jun 30, 2019 | $0.14 | $0.10 | N/A | +40.00% | Beat | +55.6% | 4 | N/A | Jul 31, 2019 | $39.66M |
| Mar 31, 2019 | $0.09 | $0.05 | N/A | +80.00% | Beat | +125.0% | 4 | N/A | May 1, 2019 | $32.58M |
| Dec 31, 2018 | $0.07 | $0.02 | N/A | +250.00% | Beat | +250.0% | 4 | N/A | Feb 21, 2019 | $31.19M |
| Sep 30, 2018 | $0.07 | -$0.03 | -$0.06 - -$0.02 | +333.33% | Beat | +75.0% | 5 | N/A | Oct 31, 2018 | $31.77M |
| Jun 30, 2018 | $0.09 | $0.01 | -$0.02 - $0.01 | +800.00% | Beat | N/A | 5 | N/A | Aug 1, 2018 | $33.91M |
| Mar 31, 2018 | $0.04 | -$0.04 | -$0.06 - -$0.02 | +200.00% | Beat | N/A | 5 | N/A | May 2, 2018 | $27.09M |
| Dec 31, 2017 | $0.02 | -$0.01 | -$0.06 - $0.02 | +300.00% | Beat | 0.0% | 5 | N/A | Feb 28, 2018 | $24.85M |
| Sep 30, 2017 | $0.04 | $0.02 | N/A | +100.00% | Beat | N/A | 4 | N/A | Nov 8, 2017 | $23.47M |
| Jun 30, 2017 | -$0.01 | -$0.03 | -$0.07 - -$0.03 | +66.67% | Beat | N/A | 4 | N/A | Aug 2, 2017 | $21.94M |
| Mar 31, 2017 | -$0.04 | -$0.06 | N/A | +33.33% | Beat | N/A | N/A | N/A | May 3, 2017 | $20.35M |
| Dec 31, 2016 | $0.02 | -$0.02 | N/A | +200.00% | Beat | +100.0% | N/A | N/A | Mar 2, 2017 | $22.14M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.82, after $0.01 the year before. It was -$0.03 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.82 | -8320.0% |
| Dec 31, 2024 | $0.01 | -99.0% |
| Dec 31, 2023 | $1.04 | -14.8% |
| Dec 31, 2022 | $1.22 | +40.2% |
| Dec 31, 2021 | $0.87 | +141.7% |
| Dec 31, 2020 | $0.36 | -23.4% |
| Dec 31, 2019 | $0.47 | +74.1% |
| Dec 31, 2018 | $0.27 | +2600.0% |
| Dec 31, 2017 | $0.01 | N/A |
| Dec 31, 2016 | -$0.03 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,000 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,015 | 11 | |
| 2026Q2 | Jun 30, 2026 | 6,902 | 12 | |
| 2026Q1 | Mar 31, 2026 | 6,281 | 12 | |
| 2025Q4 | Dec 31, 2025 | 6,763 | 12 | |
| 2025Q1 | Mar 31, 2025 | 8,695 | 10 | |
| 2024Q4 | Dec 31, 2024 | 10,587 | 15 | |
| 2024Q3 | Sep 30, 2024 | 4,078 | 8 | |
| 2024Q2 | Jun 30, 2024 | 6,420 | 11 |
2026Q3 Earnings Call
Opening remarks
Connie Johnson Director of Investor Relations Thank you, operator. Good afternoon, and thank you for joining us. On the call today are Warren Foust, President and Chief Executive Officer of STAAR Surgical; and Deborah Andrews, Executive Vice President and Chief Financial Officer of STAAR Surgical. Earlier today, we reported our third quarter 2026 results. We posted our results release and shareholder letter to our investor website at investors.staar.com. Today's call is scheduled for 1 hour and will include Q&A for publishing analysts. We also invite webcast participants to send questions to ir@staar.com. Before we get started, during today's discussion, we will be making forward-looking statements. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Please read the disclosures in today's release and our SEC filings. Except as required by law, STAAR assumes no obligation to update these statements to reflect future events or actual outcomes. We will also reference certain non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA per diluted share, free cash flow, and results excluding the China deferred sales. Please refer to today's release for additional information and applicable reconciliations to the most directly comparable GAAP measures. Unless otherwise specified, all comparisons will be year-over-year. Finally, we intend to use our investor website to disclose material nonpublic information and comply with Regulation FD. Please monitor that website along with our press releases, SEC filings, and public calls and webcast. With that, I would like to turn the presentation over to Warren. Warren?
Warren Foust President and Chief Executive Officer Thank you, Connie. Good afternoon, everyone, and thank you for joining us. At the start of the year, we set 3 goals: revenue growth, profit expansion, and innovation acceleration. Through the first 9 months, we've made progress on all 3. Year-to-date, we delivered record revenue, achieved strong profitability, and took important steps toward bringing our next generation of products to patients. Our strong cash flow and debt-free balance sheet give us flexibility to keep investing in that future. I want to thank our teams in China and Japan, our 2 largest markets, as well as all of our dedicated employees in Switzerland and the United States and all around the world. This year, they implemented a new ERP system, completed the move of China-bound ICL manufacturing to Switzerland, ramped production to support the EVO+ launch in China, and began the clinical trial process for 2 new lenses, all while continuing to serve surgeons and patients. That is a lot of change, and they have delivered and continue to do so, strengthening how we operate and laying further groundwork for future growth. Now let's talk about where we stand.
Frequently Asked Questions About STAA
Did STAA beat earnings estimates last quarter?
Yes. STAAR Surgical Company reported EPS of $0.26 for the quarter ended Sep 30, 2026, above the $0.05 estimate, a 420.00% surprise.
What EPS do analysts expect from STAA next quarter?
The consensus EPS estimate for STAAR Surgical Company for the quarter ending Dec 31, 2026 is -$0.06 from 12 analysts, with estimates from -$0.13 to $0.00.
How often does STAA beat earnings estimates?
STAAR Surgical Company beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +171.12%.
STAA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts